RecruitingNot applicableNCT05773729

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

Studying Beta-thalassemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai BDgene Co., Ltd.
Principal Investigator
Chen Jing, M.D.
Shanghai Children's Medical Center
Intervention
BD211(genetic)
Enrollment
10 enrolled
Eligibility
3-18 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Shanghai Children's Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05773729 on ClinicalTrials.gov

Other trials for Beta-thalassemia

Additional recruiting or active studies for the same condition.

See all trials for Beta-thalassemia

← Back to all trials